Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
spartalizumab + taminadenant
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Spartalizumab + taminadenant is a combination therapy consisting of two distinct agents. Spartalizumab is a monoclonal antibody that binds to programmed cell death-1 (PD-1), blocking its interaction with programmed cell death ligand-1 (PD-L1) to restore effector T-cell function. Taminadenant (PBF509/NIR178) is a potent and selective adenosine 2A receptor (A2AR) antagonist that inhibits A2AR expressed on T lymphocytes, thus abrogating the adenosine/A2AR-mediated inhibition of T-lymphocytes and activating a T-cell-mediated immune response against tumor cells. The combination aims to enhance activation of the immune system and effector function against cancer cells.
- Other names
- PBF509 + PDR001
02
Targets
ADORA2A (Adenosine A₂A Receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on spartalizumab + taminadenant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on spartalizumab + taminadenant.